Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Mitomycin C-based Hyperthermic Intraperitoneal Chemotherapy After Spontaneously Ruptured Hepatocellular Carcinoma and Peritoneal Metastasis: a Randomized Controlled Trial

NCT05544253 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT05544253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05544253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Mitomycin C-based Hyperthermic Intraperitoneal Chemotherapy After Spontaneously Ruptured Hepatocellular Carcinoma and Peritoneal Metastasis: a Randomized Controlled Trial
Lead sponsor
West China Hospital
Phase
Phase 2/3
Overall status
Unknown status
Start date
October 1, 2022
Completion date
September 1, 2024
Enrollment
68 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hcc, hepatocellular carcinoma, hyperthymic, peritoneal metastasis